Newsbenzinga
Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data
· Published
Article summary
FDA briefing documents question Capricor's deramiocel efficacy in DMD, while the company defends its trial analysis ahead of July 29.
An excerpt from the original article.
Comments —
Loading comments…